Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.100    
  

 
 

AMENDMENT NO. 2 TO INTELLECTUAL PROPERTY SECURITY AGREEMENT    
  

        This AMENDMENT NO. 2 is made as of the 11th day of July, 2002 (the "Amendment") by and between Kevin Kimberlin Partners, L.P., a Delaware limited partnership
("KKP"), The Immune Response Corporation, a Delaware corporation ("Seller"), Oshkim Limited Partnership ("Oshkim"), and The Kimberlin Family 1998 Irrevocable Trust (the "Trust"). 

        WHEREAS,
the Seller and the KKP entered into that certain Intellectual Property Agreement, dated as of November 9, 2001, as amended by Amendment No. 1 to Intellectual
Property Security Agreement, dated as of February 14, 2002, by and between KKP, Seller and Oshkim (the "IP Agreement"). 

        WHEREAS,
the Seller proposes to issue and sell Additional Securities (as defined in that certain Note Purchase Agreement, dated November 9, 2001, by and between KKP and Seller and
as amended) to the Trust and the Trust wishes to purchase Additional Securities from Seller. 

        WHEREAS,
the parties desire to amend the IP Agreement to add the Trust and any affiliates of KKP, Oshkim and/or the Trust as parties and in certain other respects as set forth below. 

        NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties hereby amend the IP Agreement and agree as follows: 

        1.    Effective
as of the date of this Amendment, the IP Agreement is hereby amended as follows: 

	a.
	The
Trust and any affiliates of KKP, Oshkim and/or the Trust shall be parties to the IP Agreement.

	b.
	All
references in the IP Agreement to "Lender" shall be deemed to refer to the Trust, Oshkim, KKP and any affiliates of the foregoing. 

        2.    Except
as specifically provided herein, the IP Agreement, as originally executed by the parties thereto and as amended hereby, shall remain in full force and effect. 

        3.    Any
defined terms not defined herein shall have the respective meanings set forth in the IP Agreement. 

        4.    This
Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

        5.    This
Amendment shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed entirely
within such jurisdiction. 

        IN
WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written. 

	

 	
 	

KEVIN KIMBERLIN PARTNERS, L.P.
	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	

	 	 	 	 	Name:	 	 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	

	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

OSHKIM LIMITED PARTNERSHIP
	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	

	 	 	 	 	Name:	 	 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	

	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

THE KIMBERLIN FAMILY 1998 IRREVOCABLE TRUST
	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	

	 	 	 	 	Name:	 	 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	

	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

THE IMMUNE RESPONSE CORPORATION
	

    	
 	

 	
 	

 	
 	

 
	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	

	 	 	 	 	Name:	 	 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	

QuickLinks

Exhibit 10.100

AMENDMENT NO. 2 TO INTELLECTUAL PROPERTY SECURITY AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

*Confidential portions have been omitted and filed separately with the Securities and Exchange Commission. 

 
 

Exhibit 10.39    
  

 
 

UNITED STATES
  
    DISTRIBUTION AGREEMENT    
  

        THIS AGREEMENT is made as of the 14th day of June 1996 by and between  BIOMATRIX, INC., a corporation duly organized and existing under the laws of the State of Delaware, having its principal office at 65 Railroad
Avenue, Ridgefield, New Jersey 07657, U.S.A. ("Biomatrix") and COLLAGEN CORPORATION, a corporation duly organized and existing under the laws of the
State of Delaware, having its principal office at 2500 Faber Place, Palo Alto, California 94303, U.S.A. (the "Distributor"). 

        WHEREAS, Biomatrix is engaged in the development and manufacture of the Agreement Product (as hereinafter defined); 

        WHEREAS, the Distributor desires to enter into a distribution agreement and be appointed the exclusive distributor (even to Biomatrix) of
the Agreement Product and any Improved Agreement Product(s) in the Territory (as such terms are hereinafter defined), and Biomatrix is willing to so appoint the Distributor on the terms and subject to
the conditions set forth herein; and 

        WHEREAS, the Distributor desires to purchase from Biomatrix, and Biomatrix desires to sell to the Distributor, the Distributor's orders of
the Agreement Product and any Improved Agreement Product(s) in the Territory on the terms and subject to the conditions set forth herein. 

        NOW, THEREFORE, in consideration of the premises and of the mutual covenants of the parties hereto, it is hereby agreed as follows: 

        1.    Definitions and Interpretation    

        1.1.  In
this Agreement, the following words and expressions shall have the following meanings: 

        "Affiliate"
shall mean, with respect to any party, any Person which, directly or indirectly, is controlled by, controls or is under common control with such party. For purposes of this
definition, the term "control" (including with correlative meanings, the terms "controlled by" and "under common control with") shall mean, with respect to any Person, the direct or indirect ownership
of more than fifty percent (50%) of the voting or income interest in such Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person. 

        "Agreement
Product" shall mean the one product made of hylan B and called by Biomatrix Hylaform®, the specifications for which are set forth on  Exhibit A, for use in the correction of wrinkles and
depressed scars. 

        "Agreement
Product Specifications" shall mean the specifications for the Agreement Product set forth in Exhibit A, as such
specifications may be modified or supplemented by Biomatrix from time to time in accordance with Product License Approvals or to reflect any Improved Agreement Product(s). 

        "Agreement
Year" shall mean the twelve (12) month period commencing on the date of first commercial sales of the Agreement Product in the United States and each separate
successive twelve (12) month period thereafter. 

        "Contract
Quarter" shall mean, for sales of Agreement Product, the period commencing with the Distributor's first commercial sale of the Agreement Product in the United States and ending
on the first to occur of March 31, June 30, September 30 and December 31, as applicable, and each three (3) month period thereafter throughout the term of this
Agreement. 

        "Dermal
Tissue Augmentation Products" shall mean biomaterial(s) that are [***]. 

        "Dollars"
and "$" shall mean the lawful currency of the United States of America. 

 

        "Effective
Date" shall mean June 17, 1996. 

        "EU
Countries" shall mean, collectively, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden and the United
Kingdom. 

        "European
Territory" shall mean, collectively, the EU Countries, Switzerland, Norway, Liechtenstein and Iceland. 

        "Formula
Price" shall mean an amount equal to [***] Agreement Product, provided that if the
[***] the Agreement Product in the Territory [***], then the Formula Price shall mean an amount equal to [***] of the Agreement
Product [***]. 

        "Improved
Agreement Product(s)" shall mean (i) any modification of the Agreement Product (made entirely from hylan B) regarding the formulation of hylan B in the Agreement
Product, that is changes of concentration of the polymer or other changes in the Agreement Product Specifications, whether or not requiring new regulatory approval in the EU Countries or in the United
States, and (ii) any modifications or changes related to the packaging of the Agreement Product, including the syringe used, mode of application or dosage. 

        "Incremental
Royalties" shall mean that term as defined in Section 8.2. 

        "Initial
Term" shall mean that term as defined in Section 3.2. 

        "International
Agreement" means the Distribution Agreement between Biomatrix and Distributor, dated as of the date hereof, relating to the sale of the Agreement Product in the EU
Countries,
Switzerland, Norway, Liechtenstein, Iceland, Australia, New Zealand, Canada, Israel, Argentina, Mexico, Chile and Brazil. 

        "International
Territory" shall mean, collectively, the EU Countries, Switzerland, Norway, Liechtenstein, Iceland, Australia, New Zealand and Japan, Israel, Argentina, Brazil, Chile,
Mexico and Canada. 

        "Launch"
shall mean the commencement by the Distributor of sales of the Agreement Product in commercial quantities in the Territory for use in the Territory. 

        "Minimum
Price" shall mean an amount equal to [***] for each Treatment Syringe, [***], then the Minimum Price payable
[***] Agreement Years immediately following such [***] shall equal [***] for each Treatment Syringe. 

        "Net
Retail Sales" shall mean, with respect to sales of a Dermal Tissue Augmentation Product in the Territory, the aggregate gross price invoiced for retail sales of such product during
a period in such country to unaffiliated third-party purchasers [***]. It is Biomatrix's understanding that the foregoing definition is consistent with how the Distributor
reports its sales in its audited financial statements. 

        "New
Products" shall mean [***]. 

        "Patents"
shall mean Letters Patent or similar statutory rights relating to any Agreement Product and any Improved Agreement Product(s) (including any
continuation-in-part, continuation or division thereof or substitute thereof), and patent applications which are pending as of the Effective Date, in each case as set forth in  Exhibit C together
with any supplementary or complementary protection certificates therefore if and when such are granted. 

        "Person"
shall mean an individual, a corporation, limited liability company, a partnership, a trust, an unincorporated organization or a government or any agency or political subdivision
thereof. 

2

 

        "Product
License Approvals" shall mean those regulatory approvals required for the importation, promotion, marketing and sale of the Agreement Product and any Improved Agreement
Product(s) in the United States (including any reimbursement or pricing approvals). 

        "Region"
shall mean any one of the following countries or groups of countries: [***]. 

        "Supply
Forecast" shall mean that term as defined in Section 7.3(b). 

        "Territory"
shall mean the United States. 

        "Trademarks"
shall mean (i) the trademark Hylaform®, the details of which are described in Exhibit C, and
(ii) any other trademarks, as may be agreed upon in writing from time to time by the parties hereto for use by the Distributor in connection with the promotion, marketing and sale of the
Agreement Product and any Improved Agreement Product(s) under this Agreement. 

        "Treatment
Syringe" shall mean a ready-for-injection 1.0cc syringe of the Agreement Product. 

        "United
States Consumer Price Index" shall mean the Consumer Price Index, All Items, United States, as published by the Bureau of Labor Statistics. 

        1.2.  In
this Agreement, unless the context otherwise requires: 

        (a)  clause
headings are inserted for convenience of reference only and have no legal effect; 

        (b)  references
to sections, exhibits and schedules are to be construed as references to the sections of, and exhibits and schedules to, this Agreement and references to this
Agreement include its exhibits and schedules. 

        (c)  references
to (or to any specified provision of) this Agreement or any other document shall be construed as references to this Agreement, that provision or that document
as in force for the time being and as amended, varied, substituted, supplemented, restated or novated in accordance with the terms thereof or, as the case may be, with the agreement of the relevant
parties and (where such consent is, by the terms of this Agreement or the relevant document, required to be obtained as a condition to such amendment being permitted) the prior written consent of
Biomatrix; 

        (d)  words
importing the plural shall include the singular and vice versa; 

        (e)  references
to a person shall be construed as including references to an individual, firm, consortium, company, corporation, unincorporated body of persons or any State
or any agency thereof; and 

        (f)    references
to statutory provisions shall be construed as references to those provisions as replaced, amended or re-enacted from time to time. 

        2.    Appointment; Best Efforts; Exclusivity.    

        2.1.    Appointment.    

        (a)  Subject
to the terms and conditions hereinafter set forth, Biomatrix hereby appoints the Distributor as its exclusive [***] (except to the extent
set forth in Section 2.3) distributor for the promotion, marketing, sale and distribution within the Territory of the Agreement Product and any Improved Agreement Product(s) supplied by
Biomatrix or an Affiliate of Biomatrix to the Distributor pursuant to this Agreement. Such appointment does not include the right to sublicense or appoint subdistributors except to an Affiliate of
Distributor without the approval of Biomatrix; (and only for such time as such an Affiliate remains an Affiliate of Distributor). 

        (b)  Except
as specifically provided to the contrary herein, the foregoing appointment shall not be construed, by implication or otherwise, (i) to effect any sale of
proprietary Biomatrix 

3

 

technology, (ii) to grant any license relating to Biomatrix's proprietary methods of formulating, fabricating and manufacturing the Agreement Product or any Improved Agreement Product(s), or
(iii) to grant the Distributor any rights in or to any proprietary technology or Patents or Trademarks of Biomatrix. 

        2.2    Acceptance of Obligations; Best Efforts    The Distributor hereby accepts the appointment described in
Section 2.1 and hereby agrees to use its best efforts at all times during the term hereof to promote, market, sell and distribute the Agreement Product and any Improved Agreement Product(s) in
the Territory. Distributor's "best efforts" in this Section 2.2 shall mean that Distributor shall use generally the same channels and methods, exercise the same degree of effort and diligence,
and adhere to the same standards as Distributor and its Affiliates would apply in distributing their own actively-promoted pharmaceutical products, and shall be such as are commercially reasonable. 

        2.3    Conversion to Non-Exclusive Distributorship.    In the event that (i) in any Agreement Year
after and including the third Agreement Year or (ii) from, after and including the first year of the Distributor
acquiring and/or commercializing a New Product pursuant to Section 10.1(b) (and so long as (i) no force majeure condition of Distributor exists at such time pursuant to
Section 20, (ii) Biomatrix has met its supply obligations under Section 7.4 and (iii) Distributor is able to lawfully sell the Agreement Product and any Improved Agreement
Product(s) in the Territory) the Distributor's Net Retail Sales of the Agreement Product and any Improved Agreement Product(s) in the Territory, comprise less than [***] of its
Net Retail Sales of [***], including the Agreement Product and any Improved Agreement Product(s), [***], within [***] after
receipt of any such notice from Biomatrix, a shortfall of [***] with respect to the Territory for an Agreement Year by [***], Biomatrix shall have the
right to distribute the Agreement Product and Improved Agreement Product and/or engage another distributor for the Territory. From and after the date of a conversion to a non-exclusive
distribution arrangement within the Territory, the Distributor shall lose its rights hereunder to promote, market, sell and distribute within the Territory any Improved Agreement Product(s)
commercialized on or after such date. Notwithstanding the foregoing, the Distributor shall retain the exclusive right to use all trademarks under which the Distributor launched the Agreement Product
or any Improved Agreement Product(s) in the Territory. 

        3.    Term and Termination    

        3.1    Effective Date.    This Agreement shall take effect as of the Effective Date. 

        3.2    Term.    

        (a)  Unless
this Agreement is sooner terminated in accordance with the provisions of this Agreement, the term of the appointment hereunder for shall commence on the first day
of the first Agreement Year and shall end on the last day of the [***] Agreement Year (the "Initial Term"). 

        (b)  Unless
this Agreement is sooner terminated in accordance with the provisions of this Agreement, the appointment of the Distributor hereunder as exclusive distributor of
the Agreement Product shall be renewable by the Distributor, at its option, upon written notice to Biomatrix received at least [***] prior to the end of the Initial Term, for
an additional consecutive term of [***] following the date of expiration of the Initial Term, provided that the Distributor
shall only be entitled to exercise such renewal option if as of the date of expiration of the Initial Term the Distributor is not in material breach of any of its obligations under this Agreement.
Thereafter, the appointment of the Distributor as exclusive distributor of the Agreement Product shall be renewable upon the expiration of such additional [***] term, upon
written notice to Biomatrix received at least [***] prior to the end of such term for one additional consecutive renewal term of [***],  provided that, as of the date of expiration of the first renewal
term, the Distributor is not in material breach of any of its obligations under this
Agreement. For the avoidance of any doubt, 

4

 

Distributor's rights with respect to any Improved Agreement Product(s) commercialized after the [***] of the Effective Date shall terminate upon the
[***] of the Effective Date. Subject to the terms of this Agreement, Distributor shall have the right to continue to sell the Agreement Product and any Improved Agreement
Products it is then currently selling. 

        (c)  This
Agreement may be terminated by either party, by written notice to the other party, in the event that (i) a mutual decision not to Launch the Agreement
Product in such country is reached or (ii) a Launch is not commenced within the time period set forth on Exhibit B.

        (d)  In
the event that in any Agreement Year after and including the [***] Agreement Year (and so long as (i) no force majeure condition of
Distributor exits at such time pursuant to Section 20, (ii) Biomatrix has met its supply obligations under Section 7.4, and (iii) Distributor is able to lawfully sell the
Agreement Product and any Improved Agreement Product(s) in the Territory), the Distributor's Net Retail Sales of the Agreement Product and any Improved Agreement Product(s) in the Territory comprise
less than [***] in the Territory of all Dermal Tissue Augmentation Products, including the Agreement Product and any Improved Agreement Product(s), the Distributor's
distribution rights (including, without limitation, its right to use the Trademarks) under this Agreement for the Agreement Product and any Improved Agreement Product(s) in the Territory shall
terminate upon [***] after the end of the applicable Agreement Year, at the election of Biomatrix; [***]. Upon any such termination of the Distributor's
distribution rights in the Territory, the Distributor's obligation to pay any royalties pursuant to Sections 8.1 and 8.2 for any sales in the Territory after such termination shall cease, but the
Distributor shall remain obligated to pay all such royalties for sales in the Territory accrued prior to such termination. 

        (e)  Notwithstanding
any other provision of this Agreement to the contrary, Biomatrix may terminate this Agreement at any time prior to receipt of the Approved Letter (as
defined hereafter) from the U.S. Food and Drug Administration if Distributor is in material breach of the International Agreement, which material breach has not been cured within thirty
(30) days after written notice of such breach is received by Distributor. The parties expressly agree that Distributor's failure to meet or adhere to the launch schedule for the Agreement
Product for each country as set forth in the International Agreement shall be deemed a material breach of the International Agreement except to the extent that Distributor's failure to meet such
launch schedule is due to (i) Biomatrix's failure to meet its supply obligations under the International Agreement, (ii) a force majeure condition of the Distributor, or (iii) it
being unlawful for the Distributor to sell the Agreement Product or any Improved Agreement Product in the Territory, provided that such unlawfulness is not the result of any act or failure to act of
the Distributor. 

        (f)    Notwithstanding
any other provision in this Agreement to the contrary, the Distributor may terminate this Agreement upon notice to Biomatrix of the Distributor's
decision not to pay the fee called for in Section 7.1(b). 

        3.3.    Inventory.    

        (a)  Upon
termination of this Agreement for any reason, Biomatrix shall have the right (but not the obligation) to repurchase all or part of the inventory of the Agreement
Product and any Improved Agreement Product(s) held by the Distributor or its Affiliates. 

        (b)  The
price for inventory to be repurchased by Biomatrix pursuant to Section 3.3(a) above shall be the landed cost thereof actually paid by the Distributor to
Biomatrix. With respect to any quantities not repurchased by Biomatrix, the Distributor shall have the right to sell such inventory of the Agreement Product and any Improved Agreement Product(s), in
its usual and customary manner, in the ordinary course of business, for a period of six (6) months following termination of 

5

 

this Agreement and notwithstanding such termination the terms and conditions of this Agreement shall apply to such sales. 

        3.4    Insolvency.    This Agreement may be immediately terminated by either party, upon giving written notice to the
other party, in the event that the other party shall become insolvent or be declared bankrupt by a court of competent jurisdiction or shall be the subject of any reorganization (other than a corporate
reorganization effected in the ordinary course of business and not arising out of any insolvency) or winding up, receivership or dissolution, bankruptcy or liquidation proceeding, or any proceeding or
action similar to one or more of the above, in which case termination shall be effective upon such written notice. The failure of either party to give notice of termination upon obtaining knowledge of
any such event shall not be interpreted as a waiver of such party's rights under this Section 3.4, and such party reserves the right to exercise any such rights at any time after the occurrence
of any such event. 

        3.5    Breach.    This Agreement may be terminated by either party if the other party shall breach any of its payment
obligations hereunder or if Distributor shall commit a material breach of any of its warranties, covenants, conditions, obligations or agreements contained herein, provided  that such breach shall
continue for a period of thirty (30) days (ten (10) days in the event that such breach is the failure of the Distributor to pay the fee
called for in Section 7.1(b)) after written notice thereof and provided further that such terminations shall be immediately effective upon
further written notice to that effect to the breaching party after its failure to cure such breach within such applicable notice period. For avoidance of doubt, the parties agree that if a Launch is
not reached within thirty days after the time period set forth on Exhibit B, then either party may terminate this Agreement (provided that such
failure to reach a Launch is not due to (i) a force majeure condition of the Distributor, (ii) Biomatrix's failure to meet its supply obligations under Section 7.4, or
(iii) it being unlawful for the Distributor to sell the Agreement Product or any Improved Agreement Product in the Territory, provided that such unlawfulness is not the result of any act or
failure to act of the Distributor). 

        3.6.    Certain Rights Upon Termination.    Upon termination of this Agreement for any reason whatsoever, Biomatrix
shall have the following rights: 

        (a)  Biomatrix
shall have the unrestricted right to review, access, use and permit others to review, access and use, either directly or by cross-reference or incorporation or
otherwise, all information, data, investigations, preclinical and clinical protocols, marketing information disseminated by Distributor publicly to customers and patients and all information required
to be provided to Biomatrix by law, information relating to laboratory, animal and human studies, and related regulatory approvals
pertaining to the Agreement Product or any Improved Agreement Product(s) (the "Information") which are possessed or controlled by the Distributor or any of its Affiliates, or to which the Distributor
or any of its Affiliates has a right to review, access or use. The Distributor unconditionally agrees promptly to take any action and to execute and deliver to Biomatrix any documents or instruments
reasonably requested by Biomatrix to permit Biomatrix to make full use of such unrestricted right. 

        (b)  Further,
Biomatrix shall have exclusive ownership rights to the Trademarks and to all other product specific logos, slogans and other intangibles used by the distributor
solely in association with the independent sale of the Agreement Product and any Improved Agreement Product(s) (including all registrations relating thereto) possessed or controlled by the Distributor
or any of its Affiliates, and the Distributor unconditionally agrees, subject to the provisions of Section 3.3(b), (i) immediately upon termination to cease using the Trademarks and any
such logos, slogans, and marketing rights of Biomatrix or any imitations thereof and (ii) immediately to execute and deliver to Biometrics any documents or instruments reasonably requested by
Biomatrix to give full effect to the provisions of this Section 3.6. 

6

 

        (c)  In
addition, the Distributor unconditionally agrees, subject to the provisions of Section 3.3(b), that it shall, upon the request of Biomatrix, immediately inform
all relevant regulatory authorities that the Distributor is no longer a distributor of the Agreement Product or the Improved Agreement Product(s) and shall take all action and execute and deliver all
documents and instruments necessary in order to transfer to the fullest extent permitted under applicable law all registrations and Product License Approvals, or applications therefore, for the
Agreement Product or any Improved Agreement Product(s) to Biomatrix or any Person nominated by Biomatrix. 

        3.7.    Effects of Termination.    

        (a)  Upon
termination of this Agreement for any reason, the Distributor shall immediately discontinue making any representations regarding its status as a distributor for
Biomatrix and shall immediately cease conducting any activities with respect to the marketing, promotion, sale or distribution of the Agreement Product and any Improved Agreement Product(s),  provided, however, that the Distributor shall be permitted to sell inventory not repurchased by Biomatrix in accordance with Section 3.3. 

        (b)  Termination
of this Agreement shall not affect obligations of either party that may have accrued prior to the effective date of termination. Subject to Clause 3.8
below, termination of this Agreement shall be in addition to, and shall not be exclusive of or prejudicial to, any other grounds for termination or rights or remedies at law or in equity which either
party may have on account of any default of the other party. 

        3.8.    Waiver.    The Distributor hereby waives, to the extent it is able to do so under the laws of the United
States and other applicable law, any statutory rights it may have or acquire in respect of the termination of the relationship established hereby pursuant to the terms hereof, and agrees that the
rights available to it hereunder in the event of such termination are adequate and reflect the agreement of the parties. The Distributor shall not have any right to claim any indemnity for goodwill or
lost profits or any damages arising from the rightful termination of this Agreement in accordance with the terms hereof. 

        4.    Payments.    All payments hereunder shall be made in Dollars. Payments to
Biomatrix
shall be wired to an account designated by Biomatrix and the costs of any such remittance shall be borne by the Distributor. 

        5.    Withholding.    All payments to be made by the Distributor under this Agreement
shall be
made in full, free and clear of and without any deduction of or withholding for or on account of any taxes levied in any country of the Territory or elsewhere; provided  that if the Distributor shall be
required by law to make any deduction or withholding from any payment to Biomatrix then: 

        (a)  The
Distributor shall ensure that such deduction or withholding does not exceed the minimum legal liability therefor; and 

        (b)  Not
later than five (5) days before each deduction or withholding of any taxes, the Distributor shall forward to Biomatrix such documentary evidence as may be
required by Biomatrix in respect of the proposed deduction, withholding or payment; and 

        (c)  Prior
to any deduction or withholding the parties shall attempt in good faith to agree upon revised mutually acceptable pricing and/or payment terms. 

        6.    Trademarks; Agreement Product Marking; Promotional Information.    

        6.1.    Trademarks.    Subject to the provisions of Section 3.6, Biomatrix hereby licenses to the Distributor
the right to use, and hereby required solely in association with the independent sale by the Distributor of the Agreement Product and any Improved Agreement Products the use of, the 

7

 

Trademarks in the Territory during the term of this Agreement. The Distributor warrants that it shall not use any of the Trademarks at any time outside the Territory or use any of the Trademarks for
any products other than the Agreement Product and any Improved Agreement Product(s) within the Territory. The Distributor shall not use a trademark or other mark (other than a Trademark) in connection
with its distribution of the Agreement Product and any Improved Agreement Products
unless and until it has been agreed upon in writing by each of the parties and become a Trademark as defined herein. Biomatrix shall prosecute, maintain and defend the Trademarks throughout the Term
of this Agreement in the Territory. The parties shall execute a short form Trademark assignment agreement to the extent that it is necessary to record the Trademark license under this
Section 6.1. 

        6.2    Termination of Right to Use Trademarks.    Subject to the sell-out right of Section 3.3(b)
and except as otherwise provided in Section 3.6, upon termination of this Agreement, the License to use the Trademarks in the Territory shall terminate, and the Distributor unconditionally
agrees promptly to take all necessary action and execute and deliver to Biometrix all necessary documents and instruments to remove the Distributor as a registered user and/or a recorded licensee of
the Trademarks. In the event that the Distributor fails promptly upon written request by Biomatrix to comply with any of its agreements in the preceding sentence of this Section 6.2, the
Distributor hereby irrevocably consents to Biomatrix's taking any action necessary to give effect to such agreements. 

        6.3    Notice.    Each party hereto agrees promptly to notify the other in writing of any infringements or limitations
of the Trademarks by third parties which may come to its attention. 

        6.4    Labelling and Promotional Materials; Approved Use of Product    

        (a)  The
Distributor shall provide Biomatrix with labelling masters, instructions, specifications and copies of all marketing, labelling and promotional material it intends
to use relating to the Agreement Product and any Improved Agreement Product(s). All such labelling, packaging and promotional material shall be consistent with the relevant Product License Approvals
and all labelling and packaging materials shall be reviewed by Biomatrix and shall be subject to its written approval prior to use, such approval not to be unreasonably withheld. Biomatrix shall
communicate its acceptance or rejection of such labelling packaging and any major promotional materials that include claims or items impacting regulatory approvals within [***]
of its receipt thereof and if no such communication is received by Distributor from Biomatrix within such [***] Biomatrix shall be deemed to have accepted. Distributor shall
provide Biomatrix with all other major promotional materials for launches and subsequent promotions within a reasonable time prior to their use in order to allow Biomatrix to comment on such
materials. Distributor shall provide Biomatrix with copies of all other promotional materials at or prior to their use. 

        (b)  The
Distributor agrees that its promotion, marketing, sale and distribution of the Agreement Product and any Improved Agreement Product(s) in the Territory, and the
promotional materials and labelling used in connection therewith, shall be strictly in accordance with the approved use of the Agreement Product and any Improved Agreement Product(s) as specified in
the Product License Approvals and as further provided in this Agreement. Specifically, for purposes of this Agreement, the Distributor agrees [***], or unless agreed to in
writing by Biomatrix. 

        6.5.    Legend.    Subject to applicable laws and regulations in the Territory, all relevant packaging and promotional
material for the Agreement Product and any Improved Agreement Product(s) used or sold
by the Distributor shall contain (i) all applicable markings needed to keep the Trademarks enforceable throughout the Territory as reasonably specified by Biomatrix to the Distributor and
(ii) a legend which shall be displayed in a reasonably conspicuous manner on all packaging of such Agreement Product and any Improved Agreement Product(s) containing the corporate
identification logo of Biomatrix and indicating that such product has been developed and manufactured by Biomatrix, Inc., and its affiliates, 65 Railroad Avenue, Ridgefield, New Jersey, 07657
U.S.A. 

8

 

        6.6.    Promotional Support.    Biomatrix and the Distributor shall provide to each other on an ongoing basis and
without charge (to the extent not prevented by law or contract from doing so) all medical information relating to the Agreement Product and any Improved Agreement Product(s) (including summary data
from studies, clinical trials and the like as well as information regarding adverse events associated with the use of the Agreement Product), the proceedings of all symposia on the Agreement Product
and any Improved Agreement Product(s) and all promotional information that is available to such party relating to the Agreement Product and any Improved Agreement Product(s). In addition, Biomatrix
and the Distributor shall provide each other with access to such primary data and information in its possession as the other may reasonably request regarding the result of the studies contained in
such summary data referred to above. 

        6.7.    Joint Coordinating Committee.    Upon the execution of this Agreement, Biomatrix and the Distributor shall
establish a joint coordinating committee (the "Committee") to review all matters relating to product labelling, product claims, regulatory matters or clinical trials. The Committee shall consist of an
equal number, not to [***], of voting representatives from each of Biomatrix and the Distributor and shall meet [***]. In the event of a dispute between
representatives of Biomatrix and the Distributor on the Committee, a senior representative of each such party shall be appointed to resolve such dispute, and in the event such senior representatives
are unable to resolve the matter, Biomatrix's view shall prevail over the Distributor's. 

        6.8.    Recalls of the Agreement Product.    

        (a)  If
either party in good faith determines that a recall of the Agreement Product in the Territory is warranted, such party shall immediately notify the other party in
writing and shall advise such other party of the reasons underlying its determination that a recall is warranted. The parties shall consult with each other as to any action to be taken in regard to
such a recall, but in any event if after consultations either party in good faith still believes that such a recall should be undertaken, the parties shall cooperate in carrying out such recall. 

        (b)  Except
as otherwise provided in (c) below, in the event of a recall of the Agreement Product, Biomatrix shall correct any deficiency relating to its
manufacturing, packaging, testing, labelling, storing or handling of the Agreement Product for which it is responsible, if applicable, and shall at its cost replace the Agreement Product recalled. 

        (c)  Biomatrix
shall reimburse Distributor for all direct costs and expenses (including without limitation shipping, quality control testing and notification costs) incurred
by Distributor and its Affiliates as a result of any recall, except where such recall (i) is the result of the failure of the Distributor or its Affiliates to comply with their obligations
under this Agreement and/or (ii) was opposed by Biomatrix and proved to be unwarranted, in which case Distributor shall reimburse Biomatrix for all direct costs and expenses (including without
limitation shipping, quality control testing and notification costs) incurred by Biomatrix and its Affiliates as a result of such recall. 

        6.9.    Product Vigilance System.    The Distributor shall be responsible for maintaining medical device vigilance
systems, as established for the Agreement Product by Biomatrix, and shall promptly provide Biomatrix with notice of all product complaints, including medical complaints. Biomatrix shall be solely
responsible for processing, analyzing and, if necessary, reporting medical complaints to regulatory authorities. The Distributor shall provide all necessary support to Biomatrix for carrying out such
activities. 

        7.    Supply of Agreement Product.    

        7.1    General; Fee.    

        (a)  Biomatrix
agrees to sell the Agreement Product and any Improved Agreement Product(s) to the Distributor, on the terms and subject to the conditions set forth herein, for
resale by the 

9

 

Distributor within the Territory, and the Distributor shall obtain the Agreement Product and any Improved Agreement Product(s) for resale in the Territory only from Biomatrix or its Affiliates.
Biomatrix shall not sell the Agreement Product or any Improved Agreement Product(s) itself or supply or license the manufacture of the Agreement Product or any Improved Agreement Product(s) to any
third party for resale within the Territory, provided that Biomatrix's obligations under this sentence shall be subject to (i) applicable law and (ii) the provisions of this Agreement,
including Section 2.3. 

        (b)  [***]

        7.2.    Price; Adjustment; Reports; Payment.    

        (a)  The
parties shall attempt in good faith to agree in writing, prior to the Launch in each country, upon mutually acceptable supply pricing for the Distributor's purchase
of the Agreement Product and any Improved Agreement Product(s), but such pricing in any event shall not be less than the greater of
(i) the Minimum Price, or (ii) the Formula Price, except as provided in subsection (b) below. The parties shall attempt in good faith to agree in writing upon mutually acceptable
minimum pricing for the Agreement Product in sizes other than the 1.0cc Treatment Syringe and for any Improved Agreement Product(s). For any syringe with a fill volume of greater than one cc (1cc),
the Minimum Price shall be the amount calculated as [***] plus the dollar amount which equals [***] of such product with a larger fill volume
[***] of the one cc (1cc) syringe. In the event that Biomatrix's actual incremental Cost of Goods Sold exceeds such dollar amount, the Minimum Price shall be the amount
calculated as [***]. Subject to the general commercial availability of appropriate syringes for the Agreement Product, the [***] for a one and
one-half (1.5)cc syringe, [***] for a two (2.0)cc syringe, and [***] for a two and one-half (2.5)cc syringe. 

        (b)  If
Biomatrix has appointed a new distributor in the Territory pursuant to Section 2.3 and the Distributor has the right to distribute the Agreement Product and
any Improved Agreement Product(s) in the Territory, the supply pricing for the Distributor's purchase of the Agreement Product and any Improved Agreement Product(s) for resale in the Territory
[***]. 

        (c)  The
price initially payable by the Distributor to Biomatrix for each unit of the Agreement Product during each month of each Agreement Year shall be the Minimum Price
(subject to adjustment at the close of each applicable Contract Quarter and Agreement Year in accordance with Section 7.2(e) below). 

        (d)  Within
[***] after the end of each month of each Agreement Year, the Formula Price for the Agreement Product shall be calculated, and, to the
extent that such Formula Price exceeds the applicable Minimum Price for such Agreement Year, an adjustment resulting from the [***] with respect to all units of the Agreement
Product sold by the Distributor in the Territory during such monthly period, such payment to be made [***]after the end of the month following such monthly period. 

        (e)  Within
[***] after the end of each Contract Quarter and Agreement Year, the Formula Price for the Agreement Product shall be calculated and an
adjustment resulting from the [***], as appropriate, to the other party with respect to all units of the Agreement Product sold by the Distributor in the Territory during such
Contract Quarter and Agreement Year, such payment to be made within [***] after the end of such [***] period following the end of such Contract Quarter
and Agreement Year. The price calculated annually in this manner shall be the final price payable for all units of the Agreement Product sold by the Distributor or any Affiliate during such Agreement
Year. For the avoidance of doubt, the aggregate amount payable by Distributor for the Agreement Product(s) and any Improved Agreement Product(s) for any Agreement Year shall in no event be lower than
the Minimum Price multiplied by the total units sold in such Agreement Year in the Territory. 

10

  

        (f)    Within
[***] following the end of each calendar month in each Agreement Year, the Distributor shall submit to Biomatrix written reports detailing
the units and value of the Distributor's and its Affiliates' Net Retail Sales and aggregate number of units sold of the Agreement Product and any Improved Agreement Product(s) in the Territory during
the immediately preceding calendar month. 

        (g)  Within
[***] following the end of each Agreement Year, the Distributor shall submit to Biomatrix written reports detailing the Distributor's and
its Affiliates' sales of the Agreement Product and any Improved Agreement Product(s) during the immediately preceding Agreement Year, which reports shall contain the Net Retail Sales of the Agreement
Product and any Improved Agreement Product(s) in the Territory, and the aggregate number of units of the Agreement Product and any Improved Agreement Product(s) sold in the Territory during the
applicable Agreement Year. 

        (h)  All
purchases of the Agreement Product and any Improved Agreement Product(s) hereunder shall be billed and paid in Dollars within [***] after the
later of the date of delivery or the date of the Distributor's receipt of the invoice for each shipment of same to the Distributor. 

        7.3.    Sales and Supply Forecasts; Accounts.    

        (a)  Exhibit D, which shall be supplied by the Distributor within [***] of the Distributor's
receipt of notice from Biomatrix of [***], shall set forth a sales forecast of units of the Agreement Product in the Territory for the first Agreement Year. 

        (b)  Within
[***] after the end of each month of each Agreement Year in the Territory, the Distributor shall provide to Biomatrix an updated rolling
twelve (12) month monthly supply forecast for all unit sizes of the Agreement Product. Each such supply forecast described in this subsection (b) is referred to herein as a "Supply
Forecast"; provided, that updated Supply Forecasts shall not vary (whether up or down) from the immediately preceding Supply Forecast by more than
[***] with respect to each month covered by such preceding Supply Forecast. 

        (c)  The
Distributor shall maintain books of account with respect to its sales of the Agreement Product in the Territory. Biomatrix shall have the right, not more than once
during each calendar year, to have an independent accountant selected and retained by Biomatrix (reasonably acceptable to Distributor,
provided that any "big six" accounting firm shall be deemed reasonable) to inspect and examine such books of the Distributor during regular business hours for the purpose of verifying the statements
of the aggregate Net Retail Sales of all Dermal Tissue Augmentation Products for all purposes hereunder, including verification of Formula Price and the royalties described in Section 8. The
cost of each such audit shall be borne by Biomatrix unless a material error is discovered in the course of such audit, in which case the cost shall be borne by the Distributor. For purposes of this
Section 7.3(d), a material error shall be defined as an understatement of five percent (5%) or more of the aggregate amount owed to Biomatrix with respect to sales of Dermal Tissue Augmentation
Products in the Territory. Any additional payments required as a result of such inspection and examination shall be immediately paid to Biomatrix and shall bear interest from the date such amount
would otherwise have been paid until the date of actual payment at the rate per annum set forth in Section 20. Such independent accounting firm shall conduct such inspections and examinations
under conditions of confidentiality. 

        7.4.    Shipment and Delivery; Packaging; Shelf Life.    

        (a)  Biomatrix
or an Affiliate of Biomatrix shall arrange for shipment to the Distributor of the Agreement Product and any Improved Agreement Product(s) ordered by the
Distributor [***]. The Distributor shall pay all customs duties, sales taxes and other governmental charges relating to the Agreement Product and any Improved Agreement
Product(s), and shall be solely responsible for clearing such products through customs throughout the Territory. 

11

 

        (b)  The
Distributor shall submit a firm purchase order setting forth the quantities, delivery date and shipping instructions with respect to each shipment of the Agreement
Product and any Improved Agreement Product(s), such purchase orders to be received by Biomatrix at least [***] prior to the requested delivery date;  provided that the Distributor shall not submit any
purchase order for fewer than 1,000 units of the Agreement Product or the Improved Agreement
Product(s) (although multiple delivery site for purchase orders shall be allowed). Biomatrix shall have no obligation to supply Distributor with quantities of the Agreement Product(s) and Improved
Agreement Product(s) in excess of the amounts in the then current Supply Forecast for the relevant monthly period. 

        (c)  Each
unit of the Agreement Product and any Improved Agreement Products shipped to the Distributor shall have, as of the time of delivery, a remaining shelf life of no
less than [***] less than the maximum shelf life for such product, as approved by the U.S. Food and Drug Administration. Biomatrix shall continually use its best efforts at all
times during the term hereof to lengthen to [***] the shelf life of the Agreement Product and any Improved Agreement Products to the extent supported by stability data.
Biomatrix' "best efforts" in this section shall mean that Biomatrix shall use such methods, exercise such degree of effort and diligence, and adhere to such standards as are commercially reasonable. 

        7.5.    Title.    Legal title to all quantities of the Agreement Product and any Improved Agreement Product(s) sole
hereunder shall remain in Biomatrix until delivery of the Agreement Product and any Improved Agreement Product(s) to Distributor or its agent and acceptance thereof, and upon such delivery and
acceptance the title to such Agreement Product and any Improved Agreement Product(s) shall, without further action, be transferred to and vested in the Distributor. 

        7.6.    Risk of Loss.    Biomatrix shall bear all risk of loss of, or damage to, all units of the Agreement Product
and any Improved Agreement Product(s) to the extent the same is in its possession or the possession of its Affiliates, nominees or agents. The Distributor shall bear all risk of loss of, or damage to,
all units of the Agreement Product and any Improved Agreement Product(s) after delivery to a common carrier for shipment to the Distributor in accordance with Section 7.4. 

        7.7.    Acceptance.    [***]. All units of the Agreement Product and Improved Agreement
Products delivered to Distributor pursuant to this Agreement shall be [***], the specification listed in Exhibit A. Any
non-conformity which arises after acceptance by Distributor directly associated with Product specification shall be the responsibility of Biomatrix unless such non-conformity
is due to improper storage conditions subsequent to delivery of the Agreement Product. All other non-conformities of the Agreement Product shall be the responsibility of the Distributor.
Biomatrix and the Distributor agree to consult with each other in order to resolve the discrepancy between each other's determinations. If such consultation does not resolve the discrepancy, the
parties agree to nominate a reputable independent laboratory, acceptable to both parties, that shall carry out tests on representative samples taken from such shipment, and the results of such tests
shall be binding on the parties. Biomatrix shall at its expense replace any such shipment to the extent that it does not conform to the Agreement Product Specifications. All defective units of the
Agreement Product or any Improved Agreement Product(s) shall be returned to Biomatrix at the address set forth in Section 23 of this Agreement, accompanied or preceded by a reasonably detailed
statement of the claimed defect or non-conformity and proof of date of purchase, and packed and shipped according to instructions provided by Biomatrix. The shipping costs of any such
returned units shall be borne by Biomatrix, unless such units are determined not to be defective under the terms of this Agreement, in which case such shipping costs shall be borne by the Distributor. 

        7.8.    Purchase Orders.    The provisions of this Agreement shall prevail over any inconsistent statement or
provisions contained in any document related to this Agreement passing between the 

12

 

parties hereto including, but not limited to, any purchase order, acknowledgment, confirmation or notice. 

        7.9.    Limited Warranty; Limitation on Liability.    

        Biomatrix
represents and warrants that the Agreement Product and any Improved Agreement Product(s) supplied to the Distributor hereunder shall: 

        (a)  conform
to the Agreement Product Specifications; and 

        (b)  be
manufactured, labelled, packaged and tested (while in the possession or control of Biomatrix) in accordance with the applicable Product License Approvals therefor and
all applicable laws and regulations in the Territory relating to the manufacture, labelling, packaging and testing of the Agreement Product, and shall be manufactured for use for the indications
specified in the applicable Product License Approvals therefor. 

        THE FOREGOING WARRANTY IS THE SOLE AND EXCLUSIVE WARRANTY GIVEN BY BIOMATRIX WITH RESPECT TO THE AGREEMENT PRODUCT, AND BIOMATRIX GIVES AND MAKES NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, OTHER THAN THE FOREGOING. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, NO IMPLIED WARRANTY OF MERCHANTABILITY, NO IMPLIED WARRANTY
OF FITNESS FOR ANY PARTICULAR PURPOSE, AND NO IMPLIED WARRANTY ARISING BY USAGE OF TRADE, COURSE OF DEALING OR COURSE OF PERFORMANCE IS GIVEN OR MADE BY BIOMATRIX OR SHALL ARISE BY OR IN CONNECTION
WITH ANY SALE OR PROVISION OF THE AGREEMENT PRODUCT BY BIOMATRIX, OR THE DISTRIBUTOR'S (OR ITS AFFILIATES') USE OR SALE OF THE AGREEMENT PRODUCT, OR BIOMATRIX'S AND/OR THE DISTRIBUTOR'S (OR ITS
AFFILIATES') CONDUCT IN RELATION THERETO OR TO EACH OTHER. NO REPRESENTATIVE OF BIOMATRIX IS AUTHORIZED TO GIVE OR MAKE ANY OTHER REPRESENTATION OR WARRANTY OR TO MODIFY THE FOREGOING WARRANTY IN ANY
WAY.

        The
limited warranty set forth in this Section 7.9 does not apply to any non-conformity of the Agreement Product or any
Improved Agreement Product(s) resulting from (a) repair or alteration by any party other than Biomatrix or its Affiliates, (b) misuse, negligence, abuse, accident, mishandling or storage
in an improper environment by any party other than Biomatrix or its Affiliates, or (c) use, handling, storage or maintenance other than in accordance with instructions and recommendations
provided by Biomatrix or its Affiliates. 

        Biomatrix's
obligation with respect to units of the Agreement Product and any Improved Agreement Product(s) which do not meet the warranty contained herein is limited to replacement of
such units of the Agreement Product or Improved Agreement Product(s) as applicable, provided that such units are returned to Biomatrix accompanied by a reasonably detailed statement of the claimed
defect or non-conformity and proof of purchase, and packed and shipped according to instructions provided by Biomatrix, and only if, upon examination by Biomatrix, such units of the
Agreement Product or Improved Agreement Product(s) are determined to have been defective under the terms of this Agreement. 

        BIOMATRIX'S LIABILITY, AND THE EXCLUSIVE REMEDY, IN CONNECTION WITH THE SALE OR USE OF THE AGREEMENT PRODUCT AND ANY IMPROVED AGREEMENT PRODUCT(S) (WHETHER BASED
ON CONTRACT, NEGLIGENCE, BREACH OF WARRANTY, STRICT LIABILITY OR ANY OTHER LEGAL THEORY), SHALL BE STRICTLY LIMITED TO BIOMATRIX'S OBLIGATIONS AS SPECIFICIALLY AND EXPRESSLY PROVIDED IN THIS SECTION
7.9 AND IN SECTION 9 BELOW. EXCEPT AS SPECIFICALLY PROVIDED IN THIS SECTION 7.9 AND IN SECTION 9 BELOW, BIOMATRIX SHALL HAVE NO LIABILITY, OBLIGATION OR RESPONSIBILITY OF ANY KIND, IN ANY WAY OR TO
ANY EXTENT, FOR  

13

 

 ANY DAMAGES, LOSSES, COSTS, EXPENSES OR LIABILITIES FOR ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE AGREEMENT PRODUCT AND ANY IMPROVED AGREEMENT PRODUCT(S) OR THE PERFORMANCE
THEREOF, OR ARISING IN ANY WAY IN CONNECTION WITH THE PURCHASE OR USE OR INABILITY TO USE THE AGREEMENT PRODUCT OR ANY IMPROVED AGREEMENT PRODUCT(S), EVEN IF BIOMATRIX HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. IN NO EVENT WHATSOEVER SHALL BIOMATRIX HAVE ANY LIABILITY, OBLIGATION OR RESPONSIBILITY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES ARISING
IN ANY WAY IN CONNECTION WITH THE AGREEMENT PRODUCT OR ANY IMPROVED AGREEMENT PRODUCT(S) OR THEIR SALE OR USE.

        8.    Royalty Payments by Distributor.    

        8.1.    Royalties for Sales of Dermal Tissue Augmentation Products.    The Distributor shall pay to Biomatrix a
royalty of [***] of the Net Retail Sales by the Distributor and its Affiliates of all Dermal Tissue Augmentation Products (other than sales of the Agreement Product and any
Improved Agreement Product(s)) in the Territory, including any countries that are added to the Territory after the Effective Date, [***]. Such royalty shall commence at the
earlier of (a) Launch of the Agreement Product in the Territory or (b) the Launch date set forth on Exhibit B; provided that if the
Launch is delayed due to Biomatrix's failure to meet its supply obligations under Section 7.4, due to a force majeure condition of Distributor or if Distributor is not able to lawfully sell the
Agreement Product in the Territory, such royalty shall not commence until Biomatrix meets its supply obligations, until Distributor is able to sell the Agreement Product in the Territory, or until
such force majeure condition ceases. Such royalty shall be paid by not later than [***] after the end of each Contract Quarter. 

        8.2.    Incremental Royalties.    The Distributor shall pay to Biomatrix the following annual royalties (the
"Incremental Royalties") on the Distributor's and its Affiliates' total incremental increases in Net Retail Sales of all Dermal Tissue Augmentation Products (including the Agreement Product and any
Improved Agreement Products(s)), in the Territory based on the incremental increases, if any, in Net Retail Sales of all Dermal Tissue Augmentation Products in each Agreement Year over a base year
amount comprised of Net Retail Sales of Dermal Tissue Augmentations Products in the twelve (12) months immediately preceding the first commercial sale of either the Agreement Product or any
Improved Agreement Product(s): 

	Sales Over

Increase in Total

Base Year Amount
	 	Royalty on Total

Incremental Sales

	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

The
Distributor's obligation to pay the Incremental Royalties shall cease in the event that the Distributor's rights to sell, distribute, market and promote the Agreement Product and any Improved
Agreement Product have become non-exclusive pursuant to Section 2.3 or have terminated pursuant to Section 3.2(d). The Incremental Royalty shall be paid by not later than
[***] after the end of each Agreement Year. For the avoidance of doubt, if the Distributor had no sales of any Dermal Tissue Augmentation Products prior to the first commercial
sale of either the Agreement Product or any Improved Agreement Product, the Distributor shall be obligated to pay a [***] royalty on Net Retail Sales of all Dermal Tissue
Augmentation products sold after such first commercial sale. 

        9.    Indemnification; Confidentiality; Public Announcement    

14

 

        9.1    Indemnification from the Distributor.    Subject to the provisions of Section 9.3, the Distributor shall
defend, indemnify and hold Biomatrix and its Affiliates and their respective directors, officers, agents and employees harmless from and against any and all liabilities, claims, damages and expenses
(including without limitation actual court costs and reasonable attorney's fees regardless of outcome) resulting from claims of third parties or arising out of: 

        (a)  [***];

        (b)  [***]

        (c)  [***];

provided, however, that upon Biomatrix being advised of any assertions of any such third party claims or suits or upon the bringing or filing of such
claims or suits by any third party against Biomatrix, Biomatrix will promptly notify the Distributor thereof and Biomatrix may, at its option, permit the Distributor's attorneys to handle and control
the defense of such claims or suits at the Distributor's cost and Biomatrix will co-operate with the Distributor in the defense thereof. The parties agree that there shall be no
settlements, whether agreed to in court or out of court, without the prior written consent of the indemnifying party. 

        9.2    Indemnification from Biomatrix.    Subject to the provisions of Section 9.3, Biomatrix shall defend,
indemnify and hold the Distributor and its Affiliates and their respective directors, officers, agents and employees harmless from and against any and all liabilities, claims, damages and expenses
(including without limitation actual court costs and reasonable attorneys' fees regardless of outcome) resulting from claims of third parties arising out of: 

        (a)  [***];

        (b)  [***]

        (c)  [***].

provided, however, that upon the Distributor being advised of any assertions of any such third party claims or suits or upon the bringing or filing of
such claims or suits by any third party against the Distributor, the Distributor will promptly notify Biomatrix thereof and, at Biomatrix's cost, permit Biomatrix's attorneys to handle and control the
defense of such claims or suits and will co-operate with Biomatrix in the defense thereof. The parties agree that there shall be no settlements, whether agreed to in court or out of court,
without the prior written consent of the indemnifying party. 

        9.3    Limitation on Liability    

        NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN SECTIONS 9.1 AND 9.2 ABOVE, OR ANY OTHER PROVISION OF THIS AGREEMENT, IN NO EVENT (INCLUDING THE FAULT,
NEGLIGENCE OR STRICT LIABILITY OF EITHER PARTY) SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES OTHER THAN TO THE EXTENT NECESSARY
TO REIMBURSE SUCH OTHER PARTY FOR DAMAGES ACTUALLY PAID TO A NON-AFFILIATED THIRD PARTY, PROVIDED THAT SUCH DAMAGES ARE OTHERWISE COVERED BY
THE PROVISIONS OF SECTION 9.1 OR SECTION 9.2, AS THE CASE MAY BE.

        9.4    Confidential Information.    All information acquired by either party (the "Recipient") from the other party or
any of its affiliates (the "Discloser") during the term of this Agreement or prior to the Effective Date, relating directly or indirectly to the present or potential business, operations, corporate,
technical or financial situation of the Discloser, or to manufacturing know-how, patents, data, test results, techniques, processes, procedures, raw materials, dealer, supplier and
customer lists, pre-clinical and clinical protocols or any improvements thereof of the Discloser ("Confidential Information") is confidential, and shall be held in trust by the Recipient
for the exclusive benefit of the 

15

 

Discloser. Unless otherwise agreed to in writing by the Discloser, the Recipient shall not at any time, either during or subsequent to the term of this Agreement, use for itself (other than in
accordance with the terms of this Agreement) or any other Person, or disclose or divulge to any person, other than to those of its employees and advisors and Affiliates who require the same for the
purposes hereof and who are bound by the same obligations of confidentiality, non-disclosure and non-use as set forth herein, any Confidential Information or any other
confidential or proprietary information of the Discloser of which the Recipient may acquire knowledge; provided, however, that the confidentiality,
non-disclosure and non-use provisions contained in this Section 9.4 shall not apply to any information or data to the extent that the Recipient: 

        (a)  shall
demonstrate by clear and convincing evidence that such information or data is known generally to persons in the trade through no act or omission of the Recipient
or any of its Affiliates; 

        (b)  is
required by any government authority to disclose such information or data, including without limitation for the purposes of obtaining and maintaining any Product
License Approvals under this Agreement; or 

        (c)  shall
demonstrate by its written records was disclosed to or created by it or its Affiliates on a non-confidential basis from a source other than the
Discloser or its Affiliates and that such disclosure or creation did not constitute a breach of any applicable confidentiality obligations. 

Confidential
Information shall be immediately returned to the Discloser upon termination of this Agreement, along with any copies, reproductions, digests, abstracts or the like of all or any part
thereof in the Recipient's possession or under Recipient's control, and upon such return any computer entries or the like relating thereto shall, to the extent legally permissible, be destroyed. Such
return (and destruction) will not affect the Recipient's obligations hereunder which shall survive indefinitely.
Notwithstanding anything herein to the contrary, the provisions of this Section 9.4 shall be subject to Biomatrix's rights under Section 3.6. 

        9.5.    Public Announcement.    Except as shall be necessary for governmental notification purposes or to comply with
applicable laws and regulations, and except as otherwise agreed to by the parties hereto in writing, the parties agree to keep the existence of this Agreement, and the transactions contemplated
hereby, strictly confidential. In the event that a party must file this document or otherwise disclose any of its subject matter pursuant to public filing requirements, such party shall seek
confidential treatment of those portions of the Agreement as the parties shall mutually agree upon; provided, however, that the Distributor must provide written notice to Biomatrix no later than
June 30, 1996 of those portions of the Agreement for which the Distributor requests confidential treatment. The parties shall agree upon the text of an initial public announcement relating to
the transactions contemplated by this Agreement as soon as possible. Any subsequent public announcements regarding this Agreement or the transactions contemplated herein shall also be agreed upon in
writing between the parties prior to any release thereof. 

        10.    New Products.    

        10.1 [***],
Distributor shall not commercialize nor begin the commercialization process with respect to or acquire any New Product anywhere in the
International Territory or the United States, either independently or in conjunction with one or more third parties, unless and until the following conditions have been satisfied: 

        (a)  Distributor
has made a commercially reasonable written offer to Biomatrix to participate with Distributor in the development and commercialization of such New Product;
and 

        (b)  Biomatrix
has failed to accept such written offer within [***] of its receipt of such offer. 

16

 

        In
the event that Biomatrix fails to accept any written offer made by Distributor pursuant to this Section 10.1 within [***] of Biomatrix's receipt
thereof, then Distributor, subject to the terms of this Agreement, shall have the right to independently or with other parties develop and/or commercialize any New Product to which such written offer
relates; provided, however, that any such New Product does not infringe upon any intellectual property rights of Biomatrix. Distributor shall not be required to make the written offer to Biomatrix set
forth in section 10.1(a) above only to the extent that it is prevented from doing so due to the patented proprietary rights of a third party. 

        (c)  At
all times during the term of this Agreement, Distributor shall notify Biomatrix in writing within [***] of each occurrence of one or more of
the following: 

	(i)
	Distributor's
entering into an agreement with one or more third parties with regard to the development, acquisition and/or commercialization of any New Product, and Distributor shall
provide to Biomatrix notice of such agreement and any and all agreements relating thereto and a non-confidential summary of such agreements; or

	(ii)
	Distributor's
commencing a clinical trial (either alone or in conjunction with a third party) with respect to any New product, together with a notice of the commencement of such
clinical trials and a list of all countries where such clinical trials will take place: or

	(iii)
	Distributor's
filing of an application (either alone or in conjunction with a third party) for marketing approval with the United States Food and Drug Administration or an
equivalent regulatory agency in any country with respect to any New Product stating in which countries any such filings have been made. 

        10.2 [***]
[***]. 

        10.3    Nothing
in this Section 10 shall be construed, by implication or otherwise, (i) to effect any sale or license of proprietary Biomatrix technology
(including any New Products), (ii) to grant any license relating to Biomatrix's proprietary methods of formulating, fabricating and manufacturing the Agreement Product, Improved Agreement
Products or New products, or (iii) to grant Distributor any rights in or to any proprietary technology or Patents or Trademarks of Biomatrix. 

        11.    Representations of Biomatrix.    Biomatrix represents, warrants and covenants
as
follows: 

        11.1    It
is a corporation duly organized and validly existing under the laws of the State of Delaware with the full power to conduct its affairs as currently conducted and
contemplated hereunder. All necessary action has been taken to enable it to execute and deliver this Agreement and perform its obligations hereunder. 

        11.2    This
Agreement is a valid and binding obligation of Biomatrix enforceable in accordance with its terms. Biomatrix has the unencumbered right to enter into this
Agreement and to fulfill its duties hereunder. It is not and will not become a party to any agreement in conflict herewith. Accordingly, Biomatrix has the right to appoint the Distributor as the
exclusive distributor of the Agreement Product in the Territory in accordance with the terms of this Agreement and such appointment will not constitute a breach of any existing contractual or other
arrangements between Biomatrix and any
Affiliated or non-Affiliated third party, nor shall it infringe the rights of any Affiliated or non-Affiliated third party. 

        11.3    No
approval, consent, order, authorization or license by, giving notice to or taking any other action with respect to, any governmental or regulatory authority is
required in connection with the execution and delivery of this Agreement by Biomatrix and the performance by Biomatrix of its obligations hereunder. 

17

 

        12.    Representation of the Distributor.    The Distributor represents, warrants and
covenants as follows: 

        12.1    It
is a corporation duly organized and validly existing under the laws of Delaware with the full power to conduct its affairs as currently conducted and contemplated
hereunder. All necessary action has been taken to enable it to execute and deliver this Agreement and perform its obligations hereunder. 

        12.2    This
Agreement is the Distributor's valid and binding obligation enforceable in accordance with its terms. The Distributor has the unencumbered right to enter into this
Agreement and to fulfill its obligations hereunder. It is not and will not become a party to any agreement in conflict herewith. Accordingly, the Distributor has the right to act as the exclusive
distributor of the Agreement Product in the Territory in accordance with the terms of this Agreement and the performance of its obligations hereunder will not constitute a breach of any existing
contractual or other arrangements between Distributor and any Affiliated or non-Affiliated third party, nor shall it infringe the rights of any Affiliated or non-Affiliated
third party. 

        12.3    No
approval, consent, order, authorization or license by, giving notice to or taking any other action with respect to any governmental or regulatory authority is
required in connection with the execution and delivery of this Agreement by the Distributor and the performance by the Distributor of its obligations hereunder. 

        13.    Insurance.    Each party hereto shall (a) obtain and maintain such
insurance
policies as are adequate to cover its respective obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated and (b) provide the other
party, upon request, with certificates of insurance confirming the existence of such insurance policies. 

        14.    Infringement.    Each of the Distributor and Biomatrix will promptly notify
the other
party in writing of any infringement of a Patent or Trademark or unauthorized disclosure or use of any Confidential
Information, of which it becomes aware in the Territory. Biomatrix shall have the exclusive right at its own cost to take all legal action in the Territory it deems necessary or advisable to eliminate
or minimize consequences of such infringement of a Patent or Trademark in the Territory. For the purpose of taking any such legal action, Biomatrix shall have the right, subject to the Distributor's
consent which consent shall not be unreasonably withheld or delayed, to use the name of the Distributor as plaintiff, either solely or jointly in accordance with the applicable rules of procedure;  provided that Biomatrix shall give the Distributor prior notice of such use of the Distributor's name. The Distributor shall promptly furnish Biomatrix
with whatever written authority may be required in order to enable Biomatrix to use the Distributor's name in connection with any such legal action, and shall otherwise cooperate fully and promptly
with Biomatrix in connection with any such action. All proceeds realized upon any judgment or settlement regarding such action shall belong to Biomatrix. 

        15.    Regulatory Activities; Clinical Trials and Marketing Studies.    

        15.1.    General.    

        (a)  Biomatrix
shall be responsible for maintaining at its cost the Product License Approvals required for the marketing and sale of the Agreement Product and any Improved
Agreement Product(s) in the Territory throughout the term of this Agreement. 

        (b)  Biomatrix
shall hold in its name all regulatory approvals required for the marketing and sale of the Agreement Product and any Improved Agreement Product(s) in the
Territory. 

        (c)  The
Distributor and Biomatrix shall provide reasonable advice and assistance to each other as may be necessary to obtain and maintain Product License Approvals. 

18

 

        (d)  During
the term of this Agreement, each party shall immediately notify the other in writing in the event that such party becomes aware of any failure of the Agreement
Product and any Improved Agreement Product(s) to comply with any of the requirements therefor specified in any Product License Approvals. 

        (e)  Each
of the Distributor and Biomatrix shall keep the other advised of regulatory interactions, activities and correspondence relating to the Agreement Product and any
Improved Agreement Product(s) on at least a quarterly basis, and any matters requiring immediate attention shall be communicated as soon as practicable. Notwithstanding the foregoing, within
[***], Biomatrix shall deliver [***] to the Distributor. 

        15.2.    Marketing Studies.    The parties agree that if any marketing-related studies are deemed necessary, such
studies will not delay the Launch in the Territory. The protocols for any marketing-related studies requested by the Distributor will be developed jointly by Biomatrix and the Distributor, and the
Distributor will be responsible for conducting and managing such studies at its own expense. Biomatrix shall have the right to audit the performance of any marketing-related studies performed by or on
behalf of the Distributor. The results of such studies will not be published or publicized in any way without the prior written approval of Biomatrix. 

        16.    Further Assurances.    The parties hereto agree to execute such further or
other
documents and assurances as are necessary from time to time in order to give effect to the provisions of this Agreement. 

        17.    Assignment.    The rights and obligations of the parties hereto shall inure to
the
benefit of and shall be binding upon the authorized successors and permitted assigns of each party. Neither party may assign its rights or obligations under this Agreement or may designate another
person to perform all or part of its obligations under this Agreement, or to have all or part of its rights and benefits under this Agreement without the prior written consent of the other party,
except to an Affiliate or to a successor of the business, by merger or otherwise, to which this Agreement relates, provided that in the case of an
assignment to an Affiliate the assigning party shall promptly notify the other party in writing of such assignment and shall remain liable (both directly and as guarantor) with respect to all
obligations so assigned. In the event of any assignment or in the event that an Affiliate of either party shall exercise rights and/or perform obligations hereunder pursuant to the terms of this
Agreement, the assignee of Affiliate, as the case may be, shall specifically assume and be bound by the provisions of the Agreement by executing and agreeing to an assumption agreement satisfactory to
the other party hereto. 

        18.    Governing Law; Arbitration; Injunctive Relief.    

        (a)  This
Agreement shall be governed by and construed in accordance with the internal and substantive laws of the State of New York, United States of America. The parties
hereby agree that the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement or any other document contemplated hereby. In the event of any
dispute touching or concerning this Agreement, the parties hereby agree to submit such dispute to their respective presidents by notice delivered in accordance with the provisions of
Section 23, and if within thirty (30) days, or such other period as is agreed upon in writing by the parties hereto, following such reference the dispute remains unresolved, to submit
the dispute for arbitration in Boston, Massachusetts under the Rules of the American Arbitration Association in effect on the date of this Agreement (the "Rules") by arbitrators appointed in
accordance with said Rules. Any decision of such arbitrators shall be written and shall be final and binding upon the parties. In any arbitration pursuant to this Section the award shall be rendered
by a majority of three (3) arbitrators, one (1) of whom shall be appointed by each party and the third of whom shall be appointed by mutual agreement of the two
(2) party-appointed arbitrators. In the event of failure of a party to appoint an arbitrator within thirty (30) days after commencement of the arbitration 

19

 

proceeding or in the event of failure of the two (2) party-appointed arbitrators to agree upon the appointment of the third arbitrator within sixty (60) days after commencement of the
arbitration proceeding, such arbitrator shall be appointed by the American Arbitration Association in accordance with the Rules. The arbitrators shall apply the governing law set forth in this
Section. Judgment upon an award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 

        (b)  Each
of the parties hereto acknowledges and agrees that damages will not be an adequate remedy for any material breach or violation of this Agreement if such material
breach or violation would cause immediate and irreparable harm (an "Irreparable Breach"). Accordingly, notwithstanding the provisions of Section 18(a) to the contrary, in the event of a
threatened or ongoing Irreparable Breach, each party hereto shall be entitled to seek, in any state or federal court in the State of New York, equitable relief of a kind appropriate in light of the
nature of the ongoing threatened Irreparable Breach, which relief may include, without limitation, specific performance or injunctive relief; provided, however,  that if the party bringing such action is
unsuccessful in obtaining the relief sought, the moving party shall pay the non-moving party's reasonable costs, including
attorney's fees, incurred in connection with defending such action. Such remedies shall not be the parties' exclusive remedies, but shall be in addition to all other remedies provided in this
Agreement. 

        19.    Severability.    In the event that any provision of this Agreement shall be
held by a
court of competent jurisdiction or by any governmental body to be invalid or unenforceable, such provision shall be deemed severable and the remaining parts and provisions of this Agreement shall
remain in full force and effect. 

        20.    Force Majeure.    Each of the parties shall be excused from the performance of
its
obligations hereunder in the event such performance is prevented by force majeure, and such excuse shall continue as long as the condition constituting such force majeure continues. For the purpose of
this Agreement, force majeure is defined as contingencies beyond the reasonable control of either party, including, without limitation, acts of God, judicial or regulatory action, war, civil
commotion, destruction of production facilities or materials by fire, earthquake or storm and labor disturbances (whether or not any such labor disturbance is within the power of the affected party to
settle). 

        21.    Interest.    Any overdue amounts payable by either party hereunder shall bear
interest
compounded monthly at the prime lending rate for Dollars published from time to time in The Wall Street Journal plus four percentage points (4%) per
annum, or, if lower, the highest rate permissible by applicable law, from the due date until the date of payment. 

        22.    No Partnership or Agency.    This Agreement and the relations hereby
established by and
between Biomatrix and the Distributor do not constitute a partnership, joint venture, agency or contract of employment between them. 

        23.    Notices.    All communications in connection with this Agreement shall be in
writing
and sent by postage prepaid first class mail, courier, or telefax, and if relating to default, late payment or termination, by certified mail, return receipt requested, telefax or courier, addressed
to each party at the address set forth at the beginning of this Agreement, in the case of Biomatrix, Attn: Chief Executive Officer, with a copy to: Justin P. Morreale, Esq., Bingham, Dana &
Gould LLP, 150 Federal Street, Boston, Massachusetts 02110, U.S.A., and in the case of the Distributor, Attn: President, with a copy to Kimberlie L. Cerrone, Esq., Venture Law Group, 2800 Sand Hill
Road, Menlo Park, California 94025, or to such other address as the addressee shall last have designated by notice to the communicating party. The date of giving any notice shall be the date of its
actual receipt. 

        24.    Survival.    The provisions of Sections 3.3, 3.6, 3.7, 3.8, 6.2, 9.1, 9.2, 9.3,
 9.4 and
9.5 of this Agreement shall survive the termination or expiration of this Agreement (as the case may be) and shall 

20

 

remain in full force and effect. The provisions of this Agreement that do not survive termination or expiration hereof (as the case may be) shall, nonetheless, be controlling on, and shall be used in
construing and interpreting the rights and obligations of the parties hereto with regard to, any dispute, controversy or claim which may arise under, out of, or in connection with this Agreement. 

        25.    Miscellaneous.    This Agreement sets forth the entire agreement between the
parties
with respect to the transactions and arrangements contemplated hereby and supersedes all prior oral or written arrangements. This Agreement may be modified or amended only by a written instrument
executed and delivered by both parties. None of the provisions of this Agreement shall be deemed to have been waived by any act or acquiescence on the part of either party except by an instrument in
writing signed and delivered by the party executing the waiver. This Agreement may be executed in several identical counterparts, each of which shall be an original, but all of which constitute one
instrument, and in making proof of this Agreement it shall not be necessary to produce or account for more than one such counterpart. 

[The
remainder of this page is intentionally left blank.] 

21

 

        IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date and year first above written. 

	 	 	COLLAGEN CORPORATION
	

 	
 	

By:	
 	

/s/  HOWARD D. PALEFSKY      
 Name: Howard D. Palefsky

Title: CHAIRMAN & CEO
	 	 	 	 	 
	 	 	BIOMATRIX, INC.
	 	 	 	 	 
	 	 	By:	 	/s/  ENDRE A. BALAZS      
 Name: Endre A. Balazs

Title: CEO

22

 
 
 

EXHIBITS    
  

	 
	 	 
	 	 

	Exhibit A	 	—	 	Agreement Product Specification and Approval Documents
	
Exhibit B	
 	

—	
 	

Launch Schedule
	
Exhibit C	
 	

—	
 	

Patents and Trademarks
	
Exhibit D	
 	

—	
 	

Sales Forecasts

23

 
 

EXHIBIT A    
    Agreement Product Specification and Approval Documents    
  

[***]

 
 

EXHIBIT B    
    Launch Schedule    
  

	 
	 	Date of Launch

	United States	 	[***]

 
 

EXHIBIT C    
    Patents and Trademarks    
  

	 
	 	Patents
	 	 

	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	[***]	 	 
	 	 	 	 	 
	 
	 	Trademarks
	 	 

	 	 	[***]	 	 

 
 

EXHIBIT D    
    Sales Forecasts(1)    
  

(Units) 

First Agreement Year  

	(1)
	 The parties acknowledge that in the event of the addition of other syringe sizes this forecast is subject to adjustment to incorporate such new sizes.  

QuickLinks

Exhibit 10.39

UNITED STATES DISTRIBUTION AGREEMENT

EXHIBITS

EXHIBIT A Agreement Product Specification and Approval Documents

EXHIBIT B Launch Schedule

EXHIBIT C Patents and Trademarks

EXHIBIT D Sales Forecasts(1)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]